Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Date:3/12/2009

CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor, Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

"We are quite excited about this trial, since there are no known therapies that to date have effectively targeted K-RAS in cancer patients," said Dr. Villalona-Calero. "If this therapy works, this could substantially impact the outlook for our patients."

This trial (REO 016) is a single arm, single-stage, open-label, Phase 2 study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which time REOLYSIN(R) may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial.

Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in K-RAS or EGFR, or EGFR gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
2. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
8. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
9. AMA Foundation Announces Seed Grant Research Recipients
10. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
11. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good chance ... Gionfriddo , about her now 20-month-old son, Kaiba. "At ... would take it and run with it." They ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, Inc., ... of viral infections, today announced that it has initiated ... its investigational, once daily, oral therapy for the treatment ... HCV-infected patients and is designed to assess both the ... is a first-in-class drug for the treatment of chronic ...
(Date:5/23/2013)... ALBUQUERQUE, N.M. , May 23, 2013  Net ... in the telemedicine market, announced today the company has ... a telemedicine staffing company based in Huntsville, ... agency that specializes in the staffing and recruitment of ... upon completion of the final agreement, which is expected ...
Breaking Medicine Technology:Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... Dune Medical Devices, Inc. today announced that the ... for filing the company,s Pre-Market Approval (PMA) application ... that the PMA application was sufficiently complete and ... MarginProbe represents a breakthrough technology that may offer ...
... WASHINGTON, May 16, 2011 During Older ... encourages America,s seniors to connect with their pharmacist to ... and available wellness opportunities. As the most accessible health ... to discuss many of the issues that arise due ...
Cached Medicine Technology:FDA Formally Accepts Dune Medical's MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status 2APhA Encourages Seniors to Connect with Their Pharmacist to Increase Wellness and Medication Knowledge 2APhA Encourages Seniors to Connect with Their Pharmacist to Increase Wellness and Medication Knowledge 3
(Date:5/23/2013)... May 23, 2013 Today, Zane Benefits, ... mandate . Zane Benefits, which provides comprehensive and flexible ... leader in defined contribution plans and ... a common question from employees is “does my employer ... website, not necessarily. The health care reform law, called ...
(Date:5/23/2013)... Mann HealthDay Reporter , , THURSDAY, May 23 ... take to help treat hip and knee osteoarthritis may ... for developing glaucoma, a small new study of older ... an increase of intraocular pressure (IOP) or pressure inside ... leading causes of blindness. In the ...
(Date:5/23/2013)... journal Science published an article about bexarotene ... an important starting point for further Alzheimer,s research. The ... at VIB and KU Leuven in collaboration with ... and scientists at Janssen Pharmaceutica, Beerse, also tested this ... results were different, as were those of two American ...
(Date:5/23/2013)... about to be tested in a clinical trial by ... for Alzheimer,s disease has failed to work with the ... according to results of a study by University of ... neuroscience affiliated with the Evelyn F. and William L. ... the importance of verifying promising research results before investing ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Dr. ... her new charitable organization in Orange County, OCCares , ... in Orange County. The event details are as follows: ... Orangewood Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 ... pop crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... was more rapid afterward, study finds , , TUESDAY, Oct. ... education seems to delay the onset of dementia, but ... a new study finds. , The findings confirm ... with more education have some kind of brain "reserve" ...
... dont dispute the important role that diet and activity ... eating habits and a less active lifestyle fully explain ... That question has led some researchers to ask whether ... In the October issue of Mayo Clinic Proceedings, researcher ...
... calls for greater collaboration across Europe on research in ... in improved and cost-effective healthcare, the ESF says, but ... and industry if Europe is to realise the full ... The call comes in a new ESF Science Policy ...
... LA JOLLA, Calif., Oct. 23 Immunosyn,Corporation (OTC Bulletin ... as the company,s Chief Executive Officer, President and,board member. ... role at Immunosyn and help,shape the company,s success. I ... life for millions of people who suffer from painful ...
... of fatigue might find some relief through regular exercise ... a new review. , Fatigue is one of ... those undergoing treatment with radiation and chemotherapy. According to ... cancer treatment experience fatigue that can range from mild ...
... McKusick-Nathans Institute of Genetic Medicine today are releasing newly ... Hopkins data, coordinated with a similar data release from ... hereditary factors and speed the understanding of autism by ... look to date at the genetic variation patterns in ...
Cached Medicine News:Health News:Dementia in More Educated Hits Later But Harder 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 3Health News:Improving Europe's image 2Health News:Immunosyn Corporation Names Stephen Ferrone as CEO 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 3Health News:Hopkins researchers release genome data on autism 2
... Hold & Support A Dropping Lens To Safely ... Phacoemulsification To ,Continue. Can Support Multiple ... Cyclodialysis Spatula To Reach Into The ... Lens Fragments With One Instrument. ,A 23g ...
... In-Line Footplates Are Turned 90 Degrees ... Diamond Blade While Incising Tissue. ,Special Mirror-Polished ... Depth Penetration.,Pre-Set Blade Extension Settings Of ... And Full Extension.,1mm Wide Snub Nose ...
... 0.1mm Pierce Tip Opening Is Designed ... The Need For A Separate Cystotome. The 11mm ... Without Elevating The Incision.,The Distal Jaws Have Platforms, ... To Prevent Inadvertent Pick Up Of Iris. The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: